Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.25% | 35.05% | 21.85% | 19.71% | 19.04% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -47.84% | -43.52% | -39.75% | -37.66% | -32.34% |
| Change in Net Operating Assets | -149.39% | -318.04% | -345.82% | -251.37% | -151.42% |
| Cash from Operations | 11.53% | 24.84% | -3.62% | -17.84% | -0.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -193.36% | -16.31% | 38.83% | 177.27% | 2.20% |
| Cash from Investing | -193.36% | -16.31% | 38.83% | 177.27% | 2.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37,856.14% | -100.00% | -100.00% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.57% | -15.20% | -171.34% | -112.23% | -191.47% |
| Cash from Financing | 231,696.04% | -830.65% | -372.00% | -312.74% | 58.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.60% | 98.09% | 94.08% | 99.33% | 82.01% |